Designing therapeutic antibodies
The work of Prof. Ami Navon focuses on designing and producing therapeutic antibodies for clinical treatment. In research that is helping to address problems related to antibody binding and efficiency—and is helping to ensure that designed therapeutic antibodies do not trigger an undesirable immune response—Prof. Navon and his team have created organic “scaffolds” that mimic the three-dimensional structure of the target protein. This scaffolding helps antibodies bind to their protein targets more effectively. As proof of concept, Prof. Navon and his team are attempting to produce antibodies against CTLA4 and PD1, two related targets involved in the activation of the immune response that have been approved for treatment of melanoma.